Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2934 in Malignant Plasma Cell Tumors
NCT07179679Phase 1Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TQB2934 in multiple myeloma (MM), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Peak time at 120 hours, Peak drug concentration at 120 hours and 4 more. Started Dec 2025; status: recruiting.
02
Drugs
TQB2934
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07179679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179679.